Trial Profile
A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 24 Weeks in Combination With Conventional Synthetic Disease-modifying Anti-rheumatic Drug(s) (csDMARDs) to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic DMARD(s) Treatment
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Jan 2024
Price :
$35
*
At a glance
- Drugs Filgotinib (Primary) ; Chloroquine; Disease-modifying antirheumatics; Hydroxychloroquine; Leflunomide; Methotrexate; Sulfasalazine
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms FINCH 2
- Sponsors Gilead Sciences
- 15 Nov 2023 Results of pooled analysis from DARWIN 1-3 (NCT01888874, NCT01894516, NCT02065700) and FINCH 1-4 (NCT02889796, NCT02873936, NCT02886728, NCT03025308) trials assessing the incidence of malignancies excluding nonmelanoma skin cancer (NMSC), NMSC, MACE and venous thromboembolism (VTE) in patients treated with FIL200 or FIL100, presented at the ACR Convergence 2023.
- 15 Nov 2023 Results of integrated safety analysis of filgotinib in patients with moderate to severe active rheumatoid arthritis from 7 clinical trials NCT01888874, NCT01894516 NCT02889796, NCT02873936, NCT02886728, NCT02065700 & NCT03025308, presented at the ACR Convergence 2023.
- 15 Nov 2023 Results of post hoc analysis of the FINCH studies assessing specific effects of filgotinib (FIL) on pain and its relationship with efficacy in patients with RA presented at the ACR Convergence 2023